Montalescot G - Search Results

1

Low molecular weight heparins in the cardiac catheterization laboratory.

Montalescot G, Cohen M. Montalescot G, et al. J Thromb Thrombolysis. 1999 Jun;7(3):319-23. doi: 10.1023/a:1008943529597. J Thromb Thrombolysis. 1999. PMID: 10373715 Review. No abstract available.

2

Endothelin-1 in patients with coronary heart disease undergoing cardiac catheterization.

Montalescot G, Viossat I, Chabrier PE, Sotirov I, Détienne JP, Drobinski G, Frank R, Grosgogeat Y, Thomas D. Montalescot G, et al. J Am Coll Cardiol. 1994 Nov 1;24(5):1236-41. doi: 10.1016/0735-1097(94)90104-x. J Am Coll Cardiol. 1994. PMID: 7930245 Free article. Clinical Trial.

3

[Low molecular weight heparin in unstable angina and myocardial infarction without Q wave].

Choussat R, Montalescot G. Choussat R, et al. Among authors: montalescot g. Presse Med. 1999 Jun 12;28(21):1128-34. Presse Med. 1999. PMID: 10399506 Review. French.

4

Low molecular weight heparin after mechanical heart valve replacement.

Montalescot G, Polle V, Collet JP, Leprince P, Bellanger A, Gandjbakhch I, Thomas D. Montalescot G, et al. Circulation. 2000 Mar 14;101(10):1083-6. doi: 10.1161/01.cir.101.10.1083. Circulation. 2000. PMID: 10715251 Clinical Trial.

5

Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis.

Collet JP, Montalescot G, Lesty C, Soria J, Mishal Z, Thomas D, Soria C. Collet JP, et al. Among authors: montalescot g. Arterioscler Thromb Vasc Biol. 2001 Jan;21(1):142-8. doi: 10.1161/01.atv.21.1.142. Arterioscler Thromb Vasc Biol. 2001. PMID: 11145946

6

[Review and future perspectives on low-molecular-weight heparin].

Collet JP, Choussat R, Montalescot G. Collet JP, et al. Among authors: montalescot g. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1233-42. Arch Mal Coeur Vaiss. 2001. PMID: 11794964 Review. French.

7

Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus.

Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch KR, Kleiman NS, Moliterno DJ, Steg PG, Teirstein P, Van de Werf F, Wallentin L. Kereiakes DJ, et al. Among authors: montalescot g. Am Heart J. 2002 Oct;144(4):615-24. doi: 10.1067/mhj.2002.124405. Am Heart J. 2002. PMID: 12360156 Review.

8

Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.

Borentain M, Montalescot G, Bouzamondo A, Choussat R, Hulot JS, Lechat P. Borentain M, et al. Among authors: montalescot g. Catheter Cardiovasc Interv. 2005 Jun;65(2):212-21. doi: 10.1002/ccd.20352. Catheter Cardiovasc Interv. 2005. PMID: 15900551 Review.

9

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.

Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators. Montalescot G, et al. N Engl J Med. 2006 Sep 7;355(10):1006-17. doi: 10.1056/NEJMoa052711. N Engl J Med. 2006. PMID: 16957147 Free article. Clinical Trial.

10

Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.

Cohen M, Bhatt DL, Alexander JH, Montalescot G, Bode C, Henry T, Tamby JF, Saaiman J, Simek S, De Swart J; SEPIA-PCI Trial Investigators. Cohen M, et al. Among authors: montalescot g. Circulation. 2007 May 22;115(20):2642-51. doi: 10.1161/CIRCULATIONAHA.106.653428. Epub 2007 May 14. Circulation. 2007. PMID: 17502577 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

784 results

Search Page